Background: The aim of our research was the quantification of interfering properties of the haemostatic drug Dicynone® (ethamsylate) in serum creatinine, uric acid, cholesterol, and triglyceride assays using the Trinder reaction.
Methods: Blood from patients was collected before and 15 minutes after administration of 500 mg Dicynone® dose i.v. and the above mentioned analytes were quantified using Roche assays (Cobas 8000). In our in vitro experiment, we measured concentrations of the analytes in pooled serum aliquots with final concentrations of Dicynone® additions 0, 30, 60, 150, and 300 mg/L. Aliquots with 60 mg/L Dicynone® were also measured at 2, 6, and 8 hours after initial measurement when stored in 22°C and 4°C for comparison.
Results: Concentrations of the measured analytes in samples from patients administered with a 500 mg dose of Dicynone® were lower in all cases (n = 10) when compared to values in samples taken immediately before treatment. The in vitro samples showed that considerable negative interference occurred even with the low concentrations of Dicynone® additions (30 and 60 mg/L), showing the strongest negative interference in creatinine values, followed by uric acid, triglycerides, and cholesterol. Using in vitro samples, we showed strong time and temperature dependence on Dicynone® interference.
Conclusions: We found and proved significant negative interference of the drug Dicynone® (ethamsylate) in the clinical analysis of blood using in vivo and in vitro experiments. Furthermore, we observed a change of this effect in serum matrix over time and at different storage temperatures.